🇺🇸 FDA
Patent

US 10954291

Monoclonal antibodies that specifically bind to matrilin-3 and their use

granted A61KA61K2039/505A61K47/6811

Quick answer

US patent 10954291 (Monoclonal antibodies that specifically bind to matrilin-3 and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K2039/505, A61K47/6811, A61K47/6843